Baraclude and Febrile neutropenia - a phase IV clinical study of FDA data

Summary:

Febrile neutropenia is found among people who take Baraclude, especially for people who are female, 60+ old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Baraclude and have Febrile neutropenia. It is created by eHealthMe based on reports of 5,842 people who have side effects when taking Baraclude from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 01, 2022

5,842 people reported to have side effects when taking Baraclude.
Among them, 44 people (0.75%) have Febrile neutropenia.


What is Baraclude?

Baraclude has active ingredients of entecavir. It is often used in hepatitis b. eHealthMe is studying from 5,902 Baraclude users for its effectiveness, alternative drugs and more.

What is Febrile neutropenia?

Febrile neutropenia (fever with reduced white blood cells) is found to be associated with 2,025 drugs and 1,765 conditions by eHealthMe.

Number of Baraclude and Febrile neutropenia reports submitted per year:

Could Baraclude cause Febrile neutropenia?

Time on Baraclude when people have Febrile neutropenia *:

  • < 1 month: 55.56 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 44.44 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Febrile neutropenia when taking Baraclude *:

  • female: 58.54 %
  • male: 41.46 %

Age of people who have Febrile neutropenia when taking Baraclude *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 2.7 %
  • 40-49: 8.11 %
  • 50-59: 27.03 %
  • 60+: 62.16 %

Common drugs people take besides Baraclude *:

  1. Aloxi: 9 people, 20.45%
  2. Lyrica: 9 people, 20.45%
  3. Zofran: 7 people, 15.91%
  4. Vidaza: 6 people, 13.64%
  5. Maxipime: 6 people, 13.64%
  6. Heparin: 5 people, 11.36%
  7. Zometa: 5 people, 11.36%
  8. Benadryl: 5 people, 11.36%
  9. Lipitor: 5 people, 11.36%
  10. Zyloprim: 4 people, 9.09%

Common side effects people have besides Febrile neutropenia *:

  1. Thrombocytopenia (decrease of platelets in blood): 12 people, 27.27%
  2. Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 10 people, 22.73%
  3. Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 9 people, 20.45%
  4. Diarrhea: 8 people, 18.18%
  5. Anaemia (lack of blood): 8 people, 18.18%
  6. White Blood Cell Count Decreased: 7 people, 15.91%
  7. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 7 people, 15.91%
  8. Dehydration (dryness resulting from the removal of water): 6 people, 13.64%
  9. Fever: 6 people, 13.64%
  10. Haemoglobin Decreased: 6 people, 13.64%

Common conditions people have *:

  1. High Blood Pressure: 10 people, 22.73%
  2. Constipation: 8 people, 18.18%
  3. Multiple Myeloma (cancer of the plasma cells): 8 people, 18.18%
  4. Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 6 people, 13.64%
  5. Burkitt Lymphoma (cancer of the lymphatic system): 6 people, 13.64%
  6. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 11.36%
  7. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 4 people, 9.09%
  8. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 3 people, 6.82%
  9. Cerebellar Haemorrhage (bleeding in cerebeller): 3 people, 6.82%
  10. Cardiac Failure: 3 people, 6.82%

* Approximation only. Some reports may have incomplete information.

Do you take Baraclude and have Febrile neutropenia?

Check whether Febrile neutropenia is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

How severe was Febrile neutropenia and when was it recovered:

Expand to all the drugs that have ingredients of entecavir:

Alternative drugs to, pros and cons of Baraclude:

Common Baraclude side effects:

Browse all side effects of Baraclude:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Febrile neutropenia treatments and more:

COVID vaccines that are related to Febrile neutropenia:

Common drugs associated with Febrile neutropenia:

All the drugs that are associated with Febrile neutropenia:

Common conditions associated with Febrile neutropenia:

All the conditions that are associated with Febrile neutropenia:

How the study uses the data?

The study uses data from the FDA. It is based on entecavir (the active ingredients of Baraclude) and Baraclude (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: